tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Dinçkan A et al. Evaluation of the first 100 liver transplantations. 2008 Turk J Gastroenterol pmid:18386237
Bajetta E et al. Merkel cell carcinoma after liver transplantation: a case report. 2007 May-Jun Tumori pmid:17679476
Vennarecci G et al. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. 2003 Jul-Aug Tumori pmid:12903579
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Nashan B et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. 2015 Trials pmid:25873064
Snyder SH et al. Neural actions of immunophilin ligands. 1998 Trends Pharmacol. Sci. pmid:9509898
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. 2003 Apr-May TreatmentUpdate pmid:17216847
Farid SG et al. Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. 2009 Transplantation pmid:19502974
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Benito N et al. Alternariosis after liver transplantation. 2001 Transplantation pmid:11740399
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Hodge G et al. Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. 2010 Transplantation pmid:20559033
Yun J et al. Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. 2010 Transplantation pmid:20559109
Schäffer MR et al. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. 1998 Transplantation pmid:9539093
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Jain A et al. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. 2014 Transplantation pmid:25285953
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Koh A et al. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. 2010 Transplantation pmid:20145529
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
Marcén R et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. 2006 Transplantation pmid:16570003
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Vennarecci G et al. Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. 2001 Transplantation pmid:11455248
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Glicklich D et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. 1998 Transplantation pmid:9721811
Eckhoff DE et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. 2000 Transplantation pmid:10830224
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Klein A et al. Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. 2009 Transplantation pmid:19300186
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Wennberg L et al. The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. 2005 Transplantation pmid:15665763
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
White M et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. 2006 Transplantation pmid:17006323
Peduto G et al. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. 2000 Transplantation pmid:10919579
Aisa Y et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. 2005 Transplantation pmid:16278584
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Tanaka J et al. The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. 2005 Transplantation pmid:16378079
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561